Know Cancer

forgot password

Psychological and Emotional Impacts of Participation in Oncologic Clinical Trials

18 Years
Open (Enrolling)
Metastatic Solid Tumor, Recurrent Hematologic Cancer

Thank you

Trial Information

Psychological and Emotional Impacts of Participation in Oncologic Clinical Trials

Inclusion Criteria:

- patient with solid tumor or recurrent hematologic cancer, treated by chemotherapy or
targeted therapy evaluated every 2 or 3 cycles; except for clinical trials
associating non drug treatment (radiotherapy, surgery...)

- subject to a 1st, 2nd or 3rd line of antitumor treatment

- a phase 2 open labeled study,

- a phase 2 or 3 blind randomised study,

- a phase 2 or 3 open randomised study,

- a standard treatment non participating to a clinical trial

- male or female patients ≥ 18 years of age

- karnovsky ≥ 70 % or OMS ≤ 2

- recovered from prior toxicities

- social security covered

- written informed consent given

Exclusion Criteria:

- psychiatric disorders, receiving psychotropic treatment

- physical or psychological issues

- forbidden to be included in this study

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

assess and compare stress and life quality of patients participating to a clinical trial vs patients treated a standard way

Outcome Description:

quality of life questionnaire (QLQ C30) Anxiety and depression questionnaire (HADS)

Outcome Time Frame:

4 years

Safety Issue:


Principal Investigator

Stéphanie CLISANT

Investigator Role:

Study Director

Investigator Affiliation:

Oscar Lambret Center


France: Committee for the Protection of Personnes

Study ID:

IPSY 0905



Start Date:

March 2011

Completion Date:

March 2016

Related Keywords:

  • Metastatic Solid Tumor
  • Recurrent Hematologic Cancer
  • stress
  • Life quality
  • adjustment strategy
  • receiving an antitumor treatment
  • within a clinical trial (case)
  • according to a standard treatment (control)
  • Hematologic Neoplasms